Predict your next investment

Private Equity

See what CB Insights has to offer

Investments

26

Portfolio Exits

11

Funds

3

About Soleus Capital Management

Soleus Capital Management is a Greenwich, CT-based healthcare investor.

Soleus Capital Management Headquarter Location

104 Field Point Road 2nd Floor

Greenwich, Connecticut, 06830,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Soleus Capital Management News

MDxHealth Shareholder Transparency Declarations

Nov 22, 2021

IRVINE, CA, and HERSTAL, BELGIUM – 22 November 2021 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "MDxHealth"), a commercial-stage precision diagnostics company, announces today in accordance with Article 14 of the Belgian Act of 2 May 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the "Belgian Transparency Act"), that it received the following notifications. MDxHealth was notified that the number of shares with respect to which Soleus Capital Management, L.P. can exercise voting rights actively crossed below the threshold of 3% of the outstanding shares and voting rights of MDxHealth on 16 November 2021. Notably, it follows from the notification that the previously reported shares of MDxHealth were held through Soleus Capital Master Fund, L.P., a limited partnership formed in the Cayman Islands. The notification also stated that the voting rights attached to the shares were exercised by the investment advisor Soleus Capital Management, L.P., a Delaware limited partnership, at its discretion, in the absence of specific instructions, that Soleus Capital Management, L.P. is controlled by a sole general partner, Soleus GP, LLC, a Delaware limited liability company, and that Soleus GP, LLC is controlled by its sole member, Mr. Guy Levy. MDxHealth was notified that the number of shares with respect to which Bleichroeder LP can exercise voting rights actively crossed above the threshold of 15% of the outstanding shares and voting rights of MDxHealth on 19 November 2021. Notably, it follows from the notification that an aggregate of 23,783,330 shares of MDxHealth, representing 15.25% of the 155,969,226 outstanding shares and voting rights of MDxHealth, is held through the following entities: 21 April Fund LP (5,824,498 shares), 21 April Fund LTD (15,042,162 shares), Hill Family Alternative Investments LLC (2,500,000 shares), and White Clover SA (416,670 shares) (the "Funds"). The notification also stated that the voting rights attached to the shares are exercised on behalf of the Funds by the investment adviser Bleichroeder LP, a Delaware limited partnership, at its discretion, in the absence of specific instructions, that Bleichroeder Holdings LLC, a Delaware limited liability company, is the general partner of Bleichroeder LP, that, as the general partner, Bleichroeder Holdings LLC holds control over voting rights of Bleichroeder LP, and that Bleichroeder Holdings LLC is not a controlled entity. For further information, reference is made to the information published on MDxHealth's website ( http://www.mdxhealth.com/investors/shareholder-information ). Pursuant to the Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority (FSMA) is required by all natural and legal persons in each case where the percentage of voting rights attached to the securities held by such persons in the Company reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company. About MDxHealth® MDxHealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers and prognosis of recurrence risk. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and U.S. headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth .com and follow us on social media at: twitter.com/mdxhealth , facebook.com/mdxhealth and linkedin.com/company/mdxhealth . For more information:

Soleus Capital Management Investments

26 Investments

Soleus Capital Management has made 26 investments. Their latest investment was in Antios Therapeutics as part of their Series B - II on November 11, 2021.

CBI Logo

Soleus Capital Management Investments Activity

investments chart

Soleus Capital Management Portfolio Exits

11 Portfolio Exits

Soleus Capital Management has 11 portfolio exits. Their latest portfolio exit was IO Biotech on November 05, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/5/2021

IPO

$991

3

9/15/2021

IPO

$991

3

5/5/2021

Corporate Majority

9

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

11/5/2021

9/15/2021

5/5/2021

00/00/0000

00/00/0000

Exit

IPO

IPO

Corporate Majority

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

3

3

9

10

10

Soleus Capital Management Fund History

3 Fund Histories

Soleus Capital Management has 3 funds, including Soleus BA SPV.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/3/2020

Soleus BA SPV

$5.65M

1

10/7/2020

Soleus Private Equity Fund I

Subscribe to see more

$99M

10

5/29/2019

Soleus BB SPV

Subscribe to see more

$99M

10

Closing Date

12/3/2020

10/7/2020

5/29/2019

Fund

Soleus BA SPV

Soleus Private Equity Fund I

Soleus BB SPV

Fund Type

Subscribe to see more

Subscribe to see more

Status

Amount

$5.65M

$99M

$99M

Sources

1

10

10

Soleus Capital Management Team

1 Team Member

Soleus Capital Management has 1 team member, including current Chief Operating Officer, Steven J Musumeci.

Name

Work History

Title

Status

Steven J Musumeci

Chief Operating Officer

Current

Name

Steven J Musumeci

Work History

Title

Chief Operating Officer

Status

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.